\n",
" \n",
" 0 | \n",
" NCT03569293 | \n",
" The objective of this study is to assess the e... | \n",
" [Placebo for Upadacitinib, Upadacitinib] | \n",
" Drug | \n",
" Tablets taken orally once a day | \n",
" [Atopic Dermatitis, Upadacitinib] | \n",
" [dermatitis, atopic, dermatitis, eczema, skin ... | \n",
"
\n",
" \n",
" 2 | \n",
" NCT03556839 | \n",
" The study will integrate the efficacy of combi... | \n",
" [Atezolizumab, Bevacizumab, Cisplatin/Carbopla... | \n",
" Drug | \n",
" Intravenous Infusion | \n",
" [Cervix, Carcinoma, Atezolizumab] | \n",
" [carcinoma, neoplasms, glandular and epithelia... | \n",
"
\n",
" \n",
" 6 | \n",
" NCT03526874 | \n",
" Migraine affects 10-28% of children and adoles... | \n",
" [Lidocaine 4% Topical Application Cream [LMX 4... | \n",
" Drug | \n",
" Run-in Step: All subjects receive 32 mg (4 cm ... | \n",
" [Episodic Migraine, Headache, Nerve Block, Pai... | \n",
" [pain, migraine disorders, headache, headache ... | \n",
"
\n",
" \n",
" 9 | \n",
" NCT03526835 | \n",
" This is a Phase 1/2 open-label, multi-center, ... | \n",
" [MCLA-158, MCLA-158 +Pembrolizumab] | \n",
" Drug | \n",
" full-length IgG1 bispecific antibody targeting... | \n",
" [Bispecific antibody, First-in-human, MCLA-158... | \n",
" [squamous cell carcinoma of head and neck, neo... | \n",
"
\n",
" \n",
" 11 | \n",
" NCT02272751 | \n",
" This study will aim to compare the effects of ... | \n",
" [Exercise, Relaxation] | \n",
" Behavioral | \n",
" The Exercise intervention will consist of aero... | \n",
" [cancer survivorship, exercise, relaxation, mi... | \n",
" [lymphoma, neoplasms by histologic type, neopl... | \n",
"
\n",
" \n",
"